KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Financing Activities (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Cash from Financing Activities for 16 consecutive years, with $239.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 197.2% to $239.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$85.2 million, a 61.08% increase, with the full-year FY2025 number at -$85.2 million, up 61.08% from a year prior.
  • Cash from Financing Activities was $239.5 million for Q4 2025 at Halozyme Therapeutics, up from -$22.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $367.8 million in Q2 2022 to a low of -$299.0 million in Q2 2025.
  • A 5-year average of -$13.6 million and a median of -$1.9 million in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 921.81% in 2022, then plummeted 26480.45% in 2023.
  • Halozyme Therapeutics' Cash from Financing Activities stood at -$156.0 million in 2021, then surged by 104.06% to $6.3 million in 2022, then plummeted by 4048.81% to -$249.9 million in 2023, then rose by 1.4% to -$246.4 million in 2024, then skyrocketed by 197.2% to $239.5 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Cash from Financing Activities are $239.5 million (Q4 2025), -$22.4 million (Q3 2025), and -$299.0 million (Q2 2025).